When was CPTx founded?

CPTx was founded in 2021 and raised its 1st funding round 3 years after it was founded.

Where is CPTx located?

CPTx is headquartered in Planegg, Germany.

Who is the current CEO of CPTx?

Hendrik Dietz of CPTx. They have also founded 1 company.

How many employees does CPTx have?

As of Sep 30, 2026, the latest employee count at CPTx is 49.

Is CPTx a funded company?

CPTx is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Sep 27, 2024.

When was the latest funding round of CPTx?

CPTx's latest funding was a $***** Series B round on Sep 27, 2024, with participation from 6 investors. Its primary sector is Infectious Diseases. In Germany, the Infectious Diseases sector has seen $22.7M in funding in 2026 to date.

Where does CPTx rank among its competitors?

CPTx ranks 530th amongst 3663 active competitors, of which 1187 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of CPTx?

CPTx's top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

CPTx - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of programmable DNA therapeutics for a range of medical challenges. The company leverages its proprietary technology to deliver precision medicine solutions, utilizing a programmable DNA-based approach to target specific diseases such as viruses, cancer, and autoimmune diseases.

Website: cptx.bio
Email ID: *****@cptx.bio
Phone Number: +49 **********

Key Metrics

Founded Year

2021

Location

Planegg, Germany

Stage

Series B

Total Funding

$29M in 1 round

Latest Funding Round

Series B, Sep 27, 2024, $*****

Investors

BlueYard & 5 more

Ranked

530^th among 3663 active competitors

Employee Count

49 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3343 more

View CPTx's full profile

CPTx has raised a total funding of $29M over 1 round. Its latest funding round was a Series B round on Sep 27, 2024 for $*****. 6 investors participated in its latest round. CPTx has 4 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of CPTx:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 27, 2024	9378616	Series B	3187692	7101117	8704621	7783395

Access funding benchmarks and valuations. Sign up today!

View details of CPTx's funding rounds and investors

The founders of CPTx is Hendrik Dietz. Hendrik Dietz is the CEO of CPTx.

Here are the details of CPTx's key team members:

Hendrik Dietz: Co-Founder & CEO of CPTx.

View details of CPTx's Founder profiles and Board Members

CPTx's employee count trend

CPTx has 49 employees as of Sep 26. Here is CPTx's employee count trend over the years:

Uncover CPTx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CPTx include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of CPTx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
530th	CPTx 2021, Planegg (Germany), Series B	Developer of programmable DNA therapeutics for a range of medical challenges	$29M	Bayern Kapital, SPRIND & 4 others	52/100